A: The Commission's independence rules apply to audits of financial statements required by SEC rules, except for those required by Rule 3-05 and 3-14 of Regulation S-X and Item 310(c) and (e) of Regulation S-B.
1 The Centers for Disease Control and Prevention (CDC) recommends 2 doses of quadrivalent meningococcal conjugate vaccine for adolescents 11 through 18 years of age.  The first dose should be given at 11 or 12 years of age, followed by a booster dose at age 16.
On October 18, 2007, FDA approved expanding the age range for Menactra, a bacterial meningitis vaccine, to include children ages 2 to 10 years. The vaccine was first approved by FDA in January 2005 for people ages 11 to 55 years. Until now, Menomune was the only meningococcal vaccine available in the United States for use in children ages 2 and older. Menactra and Menomune are manufactured by sanofi pasteur Inc. of Swiftwater, Pa.